Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2017-003234-82-GB
EUCTR2017-003234-82-GBActive, not recruitingPhase 1

A Phase III Multicenter Randomized, Sham Controlled,Study to Determine the Safety and Efficacy ofRenexus® in Macular Telangiectasia type 2 - NTMT-03-A

eurotech Pharmaceuticals0 sites112 target enrollmentStarted: October 3, 2017Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
112
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •To participate in this study, the potential participant and at least 1 of their eyes must meet all of the following criteria:
  • •1. Participant must have at least 1 study eye with a positive diagnosis of MacTel with evidence of fluorescein leakage typical of MacTel and at least one of the other features that include hyperpigmentation that is outside of a 500 micron radius from the center of the fovea, retinal opacification, crystalline deposits, right-angle vessels, or inner/outer lamellar cavities
  • •2. Participant must have an IS/OS PR break and EZ (area of IS/OS loss) as measured by SD OCT between 0.16 and 2.00 mm2
  • •3. Participant’s best-corrected visual acuity (BCVA) is 54-letter score or better (20/80 or better) as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at screening
  • •4. Participant must have steady fixation in the foveal or parafoveal area and sufficiently clear media for good quality photographs
  • •5. Participant must be greater than 21 years of age or less than 80 years of age at screening
  • •6. Participant must be able to provide written informed consent to participate in the study, in accordance with the International Conference on Harmonisation Good Clinical Practices guidelines, and local regulations, before initiating any study related procedures
  • •7. Women of childbearing potential must agree to use highly effective contraception (Germany and France only)
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 112
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 112

Exclusion Criteria

  • •To participate in this study, the potential participant must not meet any of the following criteria. The ocular exclusion criteria are related to the study eye (unless indicated for either eye):
  • •1. Participant is medically unable to comply with study procedures or follow-up visits
  • •2. Participant received intravitreal steroid therapy for non neovascular MacTel within the last 3 months
  • •3. Participant has ever received intravitreal anti-vascular endothelial growth factor (VEGF) therapy in the study eye OR has, within the past 3 months, received intravitreal anti VEGF therapy in the fellow eye at randomization
  • •4. Participant has evidence of ocular disease other than MacTel that, in the judgment of the examining physician, may confound the diagnosis, procedures, or outcome of the study (eg, glaucoma, severe nonproliferative or proliferative diabetic retinopathy, uveitis)
  • •5. Participant has a chronic requirement (eg, = 4 weeks at a time) for ocular medications and/or has a diagnosed disease that, in the judgment of the examining physician, may be vision threatening or may affect the primary outcome (artificial tears are permitted)
  • •6. Participant has evidence of intraretinal neovascularization or subretinal neovascularization (SRNV), as evidenced by hemorrhage, hard exudate, subretinal fluid or intraretinal fluid in either eye
  • •7. Participant has evidence of central serous chorio-retinopathy in either eye
  • •8. Participant has evidence of pathologic myopia in either eye
  • •9. Participant has significant corneal or media opacities in either eye
  • •10. Participant has had a vitrectomy, penetrating keratoplasty, trabeculectomy, or trabeculoplasty
  • •11. Participant has any of the following lens opacities: cortical opacity > standard 3, posterior subcapsular opacity > standard 2, or a nuclear opacity > standard 3 as measured on the Age Related Eye Disease Study (AREDS) clinical lens grading system
  • •12. Participant has undergone lens removal in the previous 3 months or YAG laser within 4 weeks
  • •13. Participant was a participant in any other clinical trial of an intervention (drug or device) within the last 6 months
  • •14. Participant is on chemotherapy
  • •15. Participant is pregnant or breastfeeding
  • •16. Participant has a history of malignancy that would compromise the 24-month study survival
  • •17. Participant with a history of ocular herpes virus in either eye
  • •18. Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations, and outcome assessments
  • •19. Participant has evidence of intraretinal hyperreflectivity by OCT

Investigators

Sponsor
eurotech Pharmaceuticals

Similar Trials

Active, not recruiting
Phase 1
A phase III clinical trial to determine the safety and effectiveness of Renexus, an implant in the eye shown to reduce the rate of progression of Macular Telangiectasia type 2Macular Telangiectasia type 2
EUCTR2017-003234-82-FReurotech Pharmaceuticals112
Active, not recruiting
Phase 1
A phase III clinical trial to determine the safety and effectiveness ofNT-501, an implant in the eye shown to reduce the rate of progression of Macular Telangiectasia type 2Macular Telangiectasia type 2
EUCTR2017-003260-12-DEeurotech Pharmaceuticals Inc.112
Unknown
Phase 3
To study the the Efficacy and Safety of Intravitreal Injection of DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
CTRI/2020/04/024680Santen Incorporated47
Active, not recruiting
Phase 1
CLINICAL STUDY FINALIZED TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD TREATMENT WITH THE LENALIDOMIDE E DEXAMETHASONE DRUGS COMPARED WITH THE DOSE REDUCTIONS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA THAT CAN NOT RECEIVE THE STANDARD CHEMIOTHERAPYELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTSMedDRA version: 18.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2013-004166-33-ITFO.NE.SA.Onlus200
Active, not recruiting
Not Applicable
An international study to assess the safety and efficacy of new investigational drugs and standard of care in patients with chronic hepatatis C virus infectioChronic Genotype 2 or 3 HCV InfectionMedDRA version: 14.1Level: LLTClassification code 10019752Term: Hepatitis C virus (HCV)System Organ Class: 10022891 - Investigations
EUCTR2011-005055-14-NLGilead Sciences Inc.500